Osteoarthritis (OA) is characterized by degenerative changes in the whole joint leading to physical disability in the elderly population. This condition is associated with altered bone metabolism in subchondral areas suggesting that therapeutic strategies aimed at modifying bone cell metabolism may be of interest. We have investigated the effects of several parathyroid hormone-related protein (PTHrP)-derived peptides (1-37): (N-terminal), (107-111) and (107-139) (C-terminal) on senescence features induced by inflammatory stress in human OA osteoblasts. Incubation of these primary cells with interleukin(IL)-1β led to an increased expression of senescence markers senescence-associated-β-galactosidase activity, γH2AX foci, p16, p21, p53, and caveolin-1. PTHrP (107-111) and PTHrP (107-139) significantly reduced all these parameters. Both peptides decreased the production of IL-6 and prostaglandin E 2 which was the consequence of cyclo-oxygenase-2 downregulation. PTHrP (107-139) also reduced tumor necrosis factor-α release. These anti-inflammatory effects would be related to the reduction of nuclear factor-κB activation by both peptides and activator protein-1 by PTHrP (107-139). The three PTHrP peptides favored osteoblastic function although the C-terminal domain of PTHrP was more efficient than its N-terminal domain. Our data support an anti-senescence and anti-inflammatory role for the C-terminal moiety of PTHrP with potential applications in chronic inflammatory conditions such as OA.
Osteoarthritis (OA) is the most common cause of pain and physical disability in the elderly population. Recent studies have demonstrated an association between hip or knee OA and frailty in communitydwelling older adults. The presence of frailty in these patients would imply more vulnerability to adverse consequences posing an additional public health burden (1, 2) . OA is characterized by changes in all components of the joint, namely cartilage degradation, synovitis, and bone alterations (3, 4) . The subchondral bone plate (the cortical endplate lying immediately deep to the calcified zone of the articular cartilage) and the subarticular spongiosa form the subchondral bone (5) . Periarticular bone changes during OA include progressive increase in subchondral plate thickness, modification in the architecture of subchondral trabecular bone, formation of new bone at the joint margins (osteophytes), as well as development of bone cysts and vascular invasion of the calcified cartilage from the subchondral bone. OA is associated with an abnormal bone metabolism and turnover in subchondral areas showing mechanically weaker sclerotic bone related to low mineralization (reviewed in (6) ).
Chronic inflammation can influence the development of OA and diseases characterized by bone loss. It is well known that proinflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor-α (TNFα) play an important role in OA as they promote catabolic processes leading to cartilage degradation and subchondral bone resorption (7) . Bone remodeling associated to inflammation depends on proinflammatory cytokines which regulate the differentiation and activity of both osteoclasts and osteoblasts (8) .
Parathyroid hormone (PTH) and PTH-related protein (PTHrP) show structural homology within the 1-13 and 29-34 sequences of both polypeptides, which determines their interaction with the common PTH type 1 receptor. The primary sequence of PTHrP differs from PTH beyond this N-terminal region and shows an extended C-terminal domain (9) . PTHrP has diverse osteogenic features, and there is current interest in various PTHrP-derived peptides as putative novel bone anabolic therapies. Specifically, a synthetic analog based on a modified N-terminal 1-34 sequence of human PTHrP (abaloparatide) has recently proven to be effective in reducing the vertebral and nonvertebral fracture risk in a Phase III clinical trial (10) . Transient exposure to the N-terminal fragment or the PTHunrelated C-terminal domain of PTHrP can increase osteoblast cell proliferation (11) and differentiation (12) . Also consistent with the osteogenic features of the C-terminal PTHrP (107-139) peptide, we previously showed that impregnation with the shorter PTHrP (107-111) peptide confers osteoconductive and osteoinductive features to several types of ceramic implants in animal models of bone repair (13) . In addition, PTHrP has the potential for cartilage repair through inhibiting chondrocyte hypertrophy (reviewed in (14) ).
At present, there is a need to develop new treatment strategies for OA as current therapies are unable to stop the disease progression. Given the contribution of osteoblasts to the regulation of cartilage metabolism and bone remodeling in OA (15) , therapeutic strategies aimed at modifying the abnormal bone cell metabolism have been suggested in this condition (16) . In this regard, previous studies have shown that PTH (1-34) exerts protective effects on both cartilage and bone in animal models of OA (17) .
Accumulation of senescent cells is believed to significantly alter tissue homeostasis and interfere with osteogenesis and regeneration (18) . It is known that chronic inflammation can promote cell senescence as it occurs in age-related diseases such as OA (19) . Of interest, studies in transgenic mice having truncated forms of PTHrP [PTHrP or PTHrP (1-84)] have suggested that the mid-and C-terminal regions of PTHrP may protect against osteoblast senescence (20) . We have recently shown that IL-1β induces an inflammatory stress response leading to senescence features in primary OA osteoblasts, thus providing an appropriate in vitro model to investigate the potential regulation of cell senescence (21) . The aim of this study was to determine and compare the ability of PTHrP (1-37) (N-terminal), PTHrP (107-111) and PTHrP (107-139) (C-terminal) to modify various senescence-related features occurring during inflammatory stress in OA osteoblasts.
Materials and Methods

Human Osteoblastic Cell Culture
The knee specimens were obtained from patients with the diagnosis of advanced OA (18 women and 8 men, aged 70.6 ± 7.2 years [mean ± SEM]) undergoing total knee joint replacement. Diagnosis was based on clinical, laboratory, and radiological evaluation. The study design was approved by the Institutional Ethical Committees (University of Valencia and University Clinical Hospital, Valencia, Spain). Samples were obtained under patient's consent according to the declaration of Helsinki. Trabecular bone samples were obtained from the femoral condyles and tibial plateaus, cut into small pieces, and subjected to enzymatic digestion with 1 mg/mL of collagenase type IA (SigmaAldrich, St. Louis, MO) at 37°C in Dulbecco's Modified Eagle's medium/Ham's F-12 (Sigma-Aldrich), supplemented with penicillin (100 U/mL) and streptomycin (100 U/mL) (Sigma-Aldrich) for 2 hours in agitation. The digested tissue was cultured in osteogenic medium (Promocell, Labclinics S.A., Barcelona, Spain) in a humidified incubator with 5% CO 2 at 37°C. This medium was replaced twice a week. When cells were at 70% of confluence, bone fragments were removed and cells were allowed to grow until confluent (2-3 weeks from the beginning of tissue culture). Cell phenotype was characterized by flow cytometry analysis using a Becton Dickinson FACSCanto II cytometer (BD, Franklin Lakes, NJ) and antibodies specific to human-CD90(1/50), CD105(1/20), CD34 (1/20) , and CD45(1/10). Studies were performed on cells at first passage (approximately 1 month after the beginning of tissue culture). Cells were negative for CD34, CD45, and CD90, and 36% positive for CD105. They expressed the osteoblastic markers Runx-2, osteocalcin, Col1A1, and Col1A2 assessed by real-time polymerase chain reaction (PCR) (21) . In all experimental procedures, subconfluent osteoblastic cells (20 × 10 3 cells/well except where indicated) were incubated with PTHrP (1-37), PTHrP (107-111) or PTHrP (107-139) (Bachem AG, Bubendorf, Switzerland) at a final concentration of 100 nM, or vehicle (distilled water), for 30 minutes before stimulation with IL-1β (10 ng/mL) (Peprotech EC, London, UK) for different times. The concentration of PTHrP peptides was selected from our previous studies as it was shown to trigger maximal responses in osteoblastic cells (11) (12) (13) .
MTT Assay
The mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) to formazan was assayed in OA osteoblasts incubated with IL-1β (10 ng/mL), with or without each PTHrP peptide (100 nM) for 1-7 days. The cells were then incubated with MTT (200 µg/mL) (Sigma-Aldrich) for 2 hours. The medium was removed and the cells were solubilized in dimethyl sulfoxide (100 µL) to quantitate formazan at 550 nm. None of the treatments significantly affected cell viability, which was more than 90% (data not shown).
Senescence-associated β-Galactosidase Activity
Senescence-associated β-galactosidase (SA-β-gal) activity was measured using the cellular senescence assay kit from Cell Biolabs (San Diego, CA). Osteoblasts seeded in Lab-tek chambers (Thermo Scientific, Rochester, NY) were incubated with IL-1β (10 ng/mL) in the presence or absence of the PTHrP peptides (100 nM) for 7 days. Cells were then fixed with 0.25% glutaraldehyde in phosphatebuffered saline (PBS), pH 7.4 for 5 minutes at room temperature, and further incubated with staining solution at 4°C overnight. Slides were mounted in Prolong Gold antifade reagent with 4′,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen, Life Technologies S.A., Madrid, Spain) and examined under a fluorescence microscope (Leica DM IL LED, Solms, Germany) for cell counting.
Immunofluorescence Assay for γH2AX Foci
Osteoblasts were seeded and incubated with the PTHrP peptides and/or IL-1β as described earlier for up to 7 days. Cells were then fixed with 4% formaldehyde in PBS for 15 minutes at room temperature and blocked with 5% normal goat serum and 0.3% Triton X-100 in PBS for 60 minutes at room temperature. Osteoblasts were further incubated with phospho-histone H2AX (Ser139) antibody (Cell Signaling Technology, Beverly, MA) overnight at 4°C. Finally, cells were incubated with Alexa Fluor 546 goat anti-rabbit IgG (H+L) (Thermo Fisher Scientific, MA), subsequently mounted in Prolong Gold antifade reagent with DAPI, and examined under a confocal microscope (Olympus FV1000, Tokyo, Japan).
Real-time PCR
Total cell RNA was extracted using the TriPure reagent (Roche Applied Science, Barcelona, Spain) according to the manufacturer's instructions. Reverse transcription was accomplished on 1 μg of total RNA using random primers (TaqMan reverse transcription reagents, Applied Biosystems, Fisher Scientific, Madrid, Spain). PCR assays were performed in duplicate on an iCycler Real-Time PCR Detection System using SYBR Green PCR Master Mix (Bio-Rad Laboratories, Richmond, CA). Primers used were synthesized by Eurofins MWG Operon (Ebersberg, Germany). Caveolin-1 primer set was from SA Biosciences Corporation (Tebu-Bio, Barcelona, Spain). For each sample, differences in threshold cycle (ΔCt) values were calculated by correcting the Ct of the gene of interest to the Ct of the reference gene β-actin. Relative gene expression was expressed as 2 −ΔΔCt with respect to nonstimulated cells.
Determination of Inflammatory Mediators
Osteoblasts were stimulated as described earlier for different times. Supernatants were harvested, centrifuged, and frozen at −80°C until analysis. TNFα and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA) kits from eBioscience (San Diego, CA) with sensitivity of 4 pg/mL and 2 pg/mL, respectively. Prostaglandin E 2 (PGE 2 ) was quantified by radioimmunoassay (22) .
Immunocytochemical Analysis for Cyclo-oxygenase-2
Osteoblasts were seeded and incubated with the PTHrP peptides and/ or IL-1β for 3 days. Cells were then subsequently fixed with 4% formaldehyde in PBS for 15 minutes and blocked with 5% bovine fetal serum in PBS for 15 minutes at room temperature. Thereafter, cells were incubated with a specific rabbit polyclonal antibody against cyclo-oxygenase-2 (COX-2; Cayman Chemical, Ann Arbor, MI) for 2 hours. Finally, cells were incubated for 1 hour with secondary anti-rabbit horseradix peroxidase (Dako, Glostrup, Denmark), followed by washing with PBS and incubation with diaminobenzidine (Vector Laboratories, Burlingame, CA). After mounting in Prolong Gold antifade reagent with DAPI, samples were examined under a microscope (Leica DM IL LED).
Activation of Transcription Factors
Osteoblasts were grown to nearly confluence in 3.5-cm 2 plates and incubated with the different PTHrP peptides in presence or absence of IL-1β for 24 hours. NF-κB (p65) and activator protein-1 (AP-1) binding to DNA were quantified by ELISA in nuclear extracts using the Nuclear Extract Kit Active Motif for nuclei extraction followed by TransAM NF-κB and AP-1 kits, respectively (Active Motif Europe, Rixensart, Belgium), according to the manufacturer's recommendations.
Immunofluorescence Assay for F-actin
Osteoblastic cells were allowed to grow until near confluence and incubated with the PTHrP peptides and/or IL-1β for 3 days. Cells were subsequently fixed with 4% formaldehyde in PBS for 10 minutes and blocked with 1% bovine serum albumin in PBS for 20 minutes at room temperature. Cells were then incubated with Alexa Fluor Phalloidin 488 (Molecular Probes, Invitrogen, Life Technologies) for 20 minutes at room temperature. Slides were processed as described earlier before examination under a confocal microscope (Olympus FV1000, Tokyo, Japan).
Mineralization Assay
The ability to form a mineralized matrix was assessed by the Alizarin red staining method using the osteogenesis quantitation kit (Chemicon/Millipore, Schwalbach, Germany), according to manufacturer's instructions. Osteoblasts (4 × 10 4 cells/well) were seeded in 24-well plates and incubated in mineralization medium (Promocell, Labclinics S.A.) in the presence or absence of the PTHrP peptides and/or IL-1β for 14 days. Cells were washed with PBS, fixed with 10% formaldehyde, rinsed with deionized water, and finally stained with Alizarin red solution for 1 hour at room temperature. After washing with deionized water, mineral deposition was examined under light microscopy (Leica DM IL LED). Quantitative analysis of Alizarin red staining was performed by extracting the dye with 10% acetic acid from the stained monolayer and measuring absorbance at 405 nm in comparison with a standard curve of Alizarin red.
Statistical Analysis
All data are expressed as mean ± SD. We performed statistical analysis by using one-way analysis of variance followed by Bonferroni's test with GraphPad Prism 5 software (Graph Pad Software, La Jolla, CA). A p value of less than .05 was considered to be significant.
Results
Modulatory Effect of PTHrP Peptides on SA-β-gal Activity Induced by IL-1β in Human OA Osteoblasts
The effect of PTHrP peptides on the senescence of OA osteoblasts induced by IL-1β after 7 days was investigated by using the biomarker of cellular senescence SA-β-gal activity. Effect of PTHrP Peptides on γH2AX Foci Accumulation by IL-1β in Human OA Osteoblasts
The γH2AX foci represent phosphorylated histone H2AX indicating DNA damage. We examined whether PTHrP peptides treatment of OA osteoblasts affected γH2AX foci accumulation. Immunofluorescence analysis showed that γH2AX foci were increased in cells incubated with IL-1β for 24 hours (Figure 2 and Supplementary Figure 2 ) and cell treatment with PTHrP (107-111) or PTHrP (107-139) significantly reduced the amount of γH2AX foci per nucleus. A higher accumulation of γH2AX foci were observed after 7 days of IL-1β stimulation, which was significantly decreased by both PTHrP (107-111) and PTHrP (107-139).
Interaction of PTHrP Peptides With IL-1β to Modulate Various Senescence Markers in Human OA Osteoblasts
We also assessed the effects of these PTHrP peptides on the expression of a number of senescence markers including p53, p21, p16, and caveolin-1 during the inflammatory response induced by IL-1β in human OA osteoblasts. As shown in Supplementary Figure 3 , this proinflammatory cytokine significantly increased the mRNA expression of all markers tested and incubation with PTHrP (107-111) or PTHrP (107-139) resulted in significantly lower levels of expression for p53, p21, p16, and caveolin-1 genes, whereas PTHrP (1-37) was only able to significantly reduce the mRNA expression of caveolin-1.
Effect of PTHrP Peptides on IL-1β Induction of Proinflammatory Cytokines in Human OA Osteoblasts
We next investigated the modulatory effects of PTHrP peptides on key proinflammatory cytokines involved in OA and cell senescence increased by IL-1β in these osteoblastic cells (7) . After 24 hours of stimulation, IL-1β strongly induced the release of TNFα, although the levels of this cytokine decreased after 3 and 7 days of culture (Supplementary Figure 4) . Only treatment with PTHrP (107-139) was found to significantly decrease TNFα in cells stimulated with IL-1β at Days 1 and 3. As shown in Supplementary Figure 5 , IL-6 was also significantly elevated by IL-1β stimulation of OA osteoblasts, reaching maximal levels at 3 and 7 days. Both PTHrP (107-111) and PTHrP (107-139) significantly reduced the production of this cytokine at 3 days, whereas PTHrP (1-37) seems to be ineffective in this regard.
Effect of PTHrP Peptides on IL-1β Stimulation of PGE 2 Production and COX-2 Expression in Human OA Osteoblasts
Many of the effects of proinflammatory cytokines on osteoblasts are mediated by the enhanced production of prostanoids, mainly PGE 2 following COX-2 induction (23). Incubation of OA osteoblasts with IL-1β resulted in the production of high levels of this prostanoid at 24 hours, which further increased at 3 and 7 days (Figure 3) . However, PGE 2 production induced by IL-1β was significantly reduced by treatment with either PTHrP (107-111) or PTHrP (107-139) at the two latter time points. In contrast, PTHrP (1-37) was ineffective to modify PGE 2 levels. We next investigated the modulatory effects of these PTHrP peptides on COX-2 expression in these cells. IL-1β significantly induced COX-2 at both protein ( Figure 4 and Supplementary Figure 6 ) and mRNA (Suppl. Figure 7 ) levels, whereas PTHrP (107-111) and PTHrP (107-139) significantly reduced COX-2 expression.
Modulatory Effect of PTHrP Peptides on Transcription Factors Induced by IL-1β in Human OA Osteoblasts
NF-κB is a key transcription factor regulating the expression of inflammation and senescence mediators (24, 25) . Figure 5A shows that IL-1β enhanced p65-DNA binding in human OA osteoblasts at 24 hours, and this stimulatory effect was decreased by both PTHrP (107-111) and PTHrP (107-139). The transcription factor AP-1 is also known to be activated by IL-1β leading to the synthesis of inflammation and senescence mediators (26) . Indeed, we found that AP-1-DNA binding increased by this cytokine in human OA osteoblasts, and this response was significantly downregulated by PTHrP (107-139) ( Figure 5B ).
Effect of PTHrP Peptides on Actin Polymerization in Human OA Osteoblasts Upon IL-1β Stimulation
We next investigated the effects of PTHrP peptides on morphological changes and cytoskeletal organization in human OA osteoblasts. Polymerization of actin fibers occurs in response to stress and also promotes osteoblast adhesion and function (27) . F-actin immunostaining showed that nontreated OA osteoblasts were well spread with thin actin stress fibers, whereas an increase in polymerized actin filaments was observed in the presence of IL-1β for 3 days (Supplementary Figure 8) . Long actin filaments were formed in cells treated with PTHrP (107-111) and to a higher extent with PTHrP (107-139), either in the presence or absence of IL-1β.
Effect of IL-1β and the PTHrP Peptides on Matrix Mineralization of Human OA Osteoblasts Cells
Deposition of a mineralized matrix is a surrogate of bone forming activity. Thus, to examine the influence of PTHrP peptides on osteoblast function in our experimental model, we assayed the mineralization ability of human OA osteoblasts. Mineralization was assessed by staining with Alizarin red to evaluate calcium-rich deposits. Figure 6 and Supplementary Figure 9 show that IL-1β weakly increased mineralization in these cell cultures relative to nonstimulated control cells. Consistent with the reported effects of PTHrP on bone formation, we observed an enhancement of mineralization by all PTHrP peptides tested in these IL-1β-treated osteoblasts. Quantification of Alizarin red confirmed that maximal levels of calcium deposition were achieved by PTHrP (107-139) either in the presence or absence of IL-1β. 
Discussion
Mechanical and biochemical functional interactions between subchondral bone and cartilage have been demonstrated (reviewed in (28)). A wide range of evidence indicates that subchondral bone changes contribute to the physiopathology of OA and subchondral osteoblasts modulate cartilage metabolism. Compared with normal osteoblasts, OA cells show increased production of proinflammatory cytokines, angiogenic factors, and matrix metalloproteinases (reviewed in (4)). Degradative enzymes and cytokines such as IL-1β, IL-6, and TNFα promote the catabolic processes leading to degeneration of cartilage and subchondral bone in OA. In addition, an increased production of inflammatory mediators is part of the cell senescence-associated secretory phenotype (29) . Our data indicate that IL-1β treatment of human OA osteoblasts results in the accumulation of γH2AX, a marker of inflammation-induced DNA damage and aging (30) . Our results also suggest that DNA damage by IL-1β triggers the senescence process in OA osteoblasts leading to increased SA-β-gal activity and expression of senescence-related markers. In addition, we show that both PTHrP (107-111) and PTHrP (107-139), in contrast to PTHrP (1-37), were able to significantly reduce these senescence features. Our data thus support an anti-senescence role for the C-terminal moiety of PTHrP, which is in line with previous results reported in transgenic mice with deletion of the mid-and C-terminus of the PTHrP molecule (20) .
IL-1β treatment of OA osteoblasts was shown to activate key transcription factors involved in the inflammatory response, namely NF-κB and AP-1 (26) . In particular, NF-κB is typically activated during the senescence process, leading to the enhanced production of inflammatory mediators such as TNFα and IL-6, as well as PGE 2 as a consequence of the observed increased expression of COX-2 after NF-κB activation (31) . Our data indicate that both PTHrP (107-111) and PTHrP (107-139) decreased the activation of NF-κB, and the latter peptide also reduced AP-1 activation, thus providing a basis for their observed anti-inflammatory actions. This may result in protective effects against bone alterations in chronic inflammatory conditions. In addition to promote cartilage degradation, proinflammatory cytokines exert complex effects on bone metabolism. Although proinflammatory cytokines can promote osteoblast differentiation or function in some cases (32) , a wide range of evidence supports the relationship between proinflammatory cytokines such as IL-1β, IL-6, and TNFα and bone resorption (reviewed in (33) ). Thus, TNFα stimulates osteoclastogenesis besides suppressing the differentiation of osteoblasts from progenitor cells and mature osteoblast functions (34) . Therefore, the modulation of inflammatory signaling has been suggested as a promising strategy for bone regeneration in osteonecrosis, osteoporosis, aging-associated bone loss, and so on (35) . In the present study, both PTHrP (107-111) and PTHrP (107-139) were shown to reduce IL-6 and TNFα production induced by IL-1β. Although a previous study reported a transient activation of NF-κB, associated with an increased expression of IL-6, by either the N-or C-terminal domains of PTHrP in primary human osteoblasts (36) , in our experimental conditions, osteoblastic cells from patients with advanced OA failed to show a significant modification of NF-κB or IL-6 responses in the absence of IL-1β stimulation.
COX-2 is upregulated during inflammatory responses and cellular senescence leading to the production of high levels of PGE 2 . In addition to their key role in inflammatory processes, enhanced COX-2 and PGE 2 may contribute to the establishment and maintenance of senescence via a PGE 2 -dependent intracrine pathway (37) . Consistent with the aforementioned results, our data indicate that PTHrP (107-111) and PTHrP (107-139) downregulated the expression of COX-2 thus decreasing the synthesis of PGE 2 which is relevant for the control of cell senescence and inflammatory bone loss. Although COX-2 and prostaglandins play a role in osteoblast differentiation and bone formation (38) , increased PGE 2 can induce the expression of receptor activator of NF-κB ligand in osteoblasts while suppressing osteoprotegerin production (39) to support osteoclastogenesis (40, 41) , and it also enhances IL-6 production in human OA osteoblasts (42) . Previous studies have shown that PTH (1-34) reduces the expression of COX-2 and matrix metalloproteinases as well as the production of inflammatory mediators in animal models of OA (43) . Our in vitro results in human OA osteoblasts suggest that, in spite of PTH homology, PTHrP (1-37) might not be as efficient as PTH in this regard. Some differences in the kinetics of interaction between N-terminal peptides of PTH and PTHrP with the same PTH type 1 receptor might explain this apparent discrepancy (44) .
Current evidence supports a role for PTHrP in osteogenic differentiation (45) . Intermittent administration of PTHrP in a mouse model of bone healing improved new bone formation by enhancing osteoblast function and angiogenesis. Similar osteogenic effects were obtained by the same pattern of administration of PTHrP (107-139) in this model (46) . Consistent with these in vivo data, our results indicate that the three PTHrP peptides evaluated favored osteoblastic function-assessed by formation of mineralized nodules-in our in vitro model of inflammatory stress in OA osteoblasts. Interestingly, the C-terminal domain of PTHrP seemed to be more efficient than its N-terminal domain at inducing cytoskeletal protein organization and promoting matrix mineralization. Proinflammatory cytokines are involved in bone resorption, but they also stimulate mineralization although cellular metabolism can be altered, and the expression of genes such as ectonucleotide pyrophosphatase/phosphodiesterase-1 is suppressed (47, 48) . However, IL-1β is able to potentiate mineralization (49) as observed in the presence of PTHrP peptides.
Our data show that the ability to control the production of inflammatory mediators and the appearance of senescence features in OA osteoblasts reside mainly in the C-terminal domain of PTHrP rather than in its N-terminus. The structure of the C-terminal tail of PTHrP is quite different from the helical conformation adopted by its N-terminal region, which predicts the existence of a specific receptor for the C-terminal domain of PTHrP (50) . Characterization of such a putative receptor is yet to be accomplished. A limitation of this study is the lack of comparison between OA and healthy osteoblasts from donors of the same age. However, the necessary samples are very difficult to obtain. Despite this limitation, the results of this study performed with human primary cells provide a foundation for a better understanding of PTHrP effects in OA osteoblasts which could help to the development of novel therapeutic approaches.
In conclusion, our present results support the notion that the anti-inflammatory and anti-senescence effects of C-terminal PTHrP peptides might be of benefit in chronic inflammatory conditions such as OA. Further in vivo studies are warranted to confirm this hypothesis.
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